Browsing Tag
Stephane Bancel
2 posts
Moderna (MRNA) surges to 52-week high as flu vaccine win and Science Day pipeline reset reframe the post-COVID story
Moderna (NASDAQ: MRNA) surges 12 percent to 52-week high above $69 on Science Day pipeline reset, FDA flu panel win and BioNTech plant acquisition plans.
Moderna rallies into a landmark FDA advisory vote on its mRNA seasonal flu vaccine
Moderna (MRNA) rallies as an FDA advisory committee weighs its mRNA seasonal flu vaccine mFlusiva, the first such vote, with a decision due August 5. Full analysis.